KR20240013145A - Alk2 키나제의 이미다졸-함유 저해제 - Google Patents

Alk2 키나제의 이미다졸-함유 저해제 Download PDF

Info

Publication number
KR20240013145A
KR20240013145A KR1020237042819A KR20237042819A KR20240013145A KR 20240013145 A KR20240013145 A KR 20240013145A KR 1020237042819 A KR1020237042819 A KR 1020237042819A KR 20237042819 A KR20237042819 A KR 20237042819A KR 20240013145 A KR20240013145 A KR 20240013145A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
cycloalkyl
mmol
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237042819A
Other languages
English (en)
Korean (ko)
Inventor
프라빈 엘. 코티안
야를라가다 에스. 바부
웨이허 장
웨이 엘브이
펑-청 루
앤드류 이. 스폴딩
크리슈난 라만
Original Assignee
바이오크리스트파마슈티컬즈,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오크리스트파마슈티컬즈,인코포레이티드 filed Critical 바이오크리스트파마슈티컬즈,인코포레이티드
Publication of KR20240013145A publication Critical patent/KR20240013145A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237042819A 2021-05-25 2022-05-24 Alk2 키나제의 이미다졸-함유 저해제 Pending KR20240013145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192822P 2021-05-25 2021-05-25
US63/192,822 2021-05-25
PCT/US2022/030690 WO2022251188A2 (en) 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase

Publications (1)

Publication Number Publication Date
KR20240013145A true KR20240013145A (ko) 2024-01-30

Family

ID=84230377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042819A Pending KR20240013145A (ko) 2021-05-25 2022-05-24 Alk2 키나제의 이미다졸-함유 저해제

Country Status (23)

Country Link
US (1) US20240270750A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346806A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520359A (cg-RX-API-DMAC7.html)
KR (1) KR20240013145A (cg-RX-API-DMAC7.html)
CN (1) CN117529315A (cg-RX-API-DMAC7.html)
AR (1) AR125963A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022283258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024537A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219966A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003503A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230597A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000254A (cg-RX-API-DMAC7.html)
EC (1) ECSP23096182A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416425A (cg-RX-API-DMAC7.html)
IL (1) IL308513A (cg-RX-API-DMAC7.html)
JO (1) JOP20230303A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013742A (cg-RX-API-DMAC7.html)
PE (1) PE20250022A1 (cg-RX-API-DMAC7.html)
PY (1) PY2240952A (cg-RX-API-DMAC7.html)
TW (1) TW202313625A (cg-RX-API-DMAC7.html)
UY (1) UY39788A (cg-RX-API-DMAC7.html)
WO (1) WO2022251188A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
BR0111754A (pt) * 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CN108239071B (zh) * 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見

Also Published As

Publication number Publication date
BR112023024537A2 (pt) 2024-02-06
UY39788A (es) 2023-01-31
JP2024520359A (ja) 2024-05-24
IL308513A (en) 2024-01-01
PY2240952A (es) 2022-12-26
EP4346806A2 (en) 2024-04-10
DOP2023000254A (es) 2023-12-29
US20240270750A1 (en) 2024-08-15
CA3219966A1 (en) 2022-12-01
AR125963A1 (es) 2023-08-30
ECSP23096182A (es) 2024-01-31
JOP20230303A1 (ar) 2023-11-23
MX2023013742A (es) 2023-11-28
WO2022251188A3 (en) 2023-01-05
AU2022283258A1 (en) 2024-01-04
PE20250022A1 (es) 2025-01-07
CR20230597A (es) 2024-02-20
CL2023003503A1 (es) 2024-05-03
WO2022251188A8 (en) 2024-01-04
WO2022251188A2 (en) 2022-12-01
CO2023017975A2 (es) 2024-01-15
EP4346806A4 (en) 2025-07-23
CN117529315A (zh) 2024-02-06
TW202313625A (zh) 2023-04-01
GEAP202416425A (en) 2024-02-12

Similar Documents

Publication Publication Date Title
AU2022219987A1 (en) Cdk inhibitors and methods of use thereof
CN114423756B (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
KR101084871B1 (ko) 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
RU2318826C2 (ru) Производные 4-амино-6-фенилпирроло[2,3] пиримидина, обладающие ингибирующим действием в отношении действия тирозинкиназы, их применение и способы получения (варианты)
ES2609087T3 (es) Derivado de dihidropirazolopirimidinona
JP2020519589A (ja) G12c変異型rasタンパク質を阻害するヘテロアリール化合物
AU2018206111B2 (en) Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof
CA3199082A1 (en) Heterocyclic spiro compounds and methods of use
JP7763772B2 (ja) 補体阻害剤としてのピロロピリミジンアミン
WO2013064083A1 (en) 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CA2860723A1 (en) Substituted imidazopyrazines as akt kinase inhibitors
US20240287071A1 (en) Class of imidazolidinopyrimidone compounds and use thereof in treatment of hsclpp-mediated diseases
KR20110075015A (ko) P70 s6 키나제 억제제 및 egfr 억제제 조합 요법
TW202313625A (zh) 含有咪唑之alk2激酶抑制劑
CA2860724A1 (en) Substituted pyrazolopyrimidines as akt kinase inhibitors
CA2821777A1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
EA052309B1 (ru) Имидазолсодержащие ингибиторы alk2-киназы
OA21894A (en) Imidazole-Containing Inhibitors Of ALK2 Kinase.
NO177749B (no) Analogifremgangsmåte ved fremstilling av 2,4,8-tri-substituerte 3H,6H-1,4,5a,8a-tetraazaace-naftylen-3,5-(4H)-dioner
EA051777B1 (ru) Пирролопиримидинамины в качестве ингибиторов комплемента
OA21436A (en) Pyrrolopyrimidine amines as complement inhibitors
CN117136052A (zh) Cdk抑制剂和其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250523

Comment text: Request for Examination of Application